Press Releases

Immunexpress.com

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by...
Immunexpress.com

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

SEATTLE, May 11, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the...
Immunexpress.com

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

SEATTLE, April 19, 2016 -- Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the University of Amsterdam to characterize and clinically evaluate sepsis and sepsis-related biomarker signatures of the host response. This four-year collaboration with AMC's Prof. Dr. Tom van der Poll and his team...
Immunexpress.com

Immunexpress Presents on the Need for an Objective Diagnostic Tool for Systemic Inflammation at the International Symposium on Intensive Care and Emergency Medicine

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data from the VENUS trial by Dr. Bert Lopansri of Intermountain Medical Center at the 36th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. The presentation describes the...
Immunexpress.com

Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial showing the discordance between clinical impressions of patients with systemic inflammation will be presented at the upcoming 36th International Symposium on Intensive Care and Emergency Medicine on Mar....
Immunexpress.com

Immunexpress Presents Results Indicating the Utility of SeptiCyte™ for the Diagnosis of Sepsis in Critically Ill Children at the 45th Annual Society of Critical Care Medicine Congress

Additional Results from the VENUS A Study Further Validate SeptiCyte as a Diagnostic Assay for Sepsis in Critically Ill Adults SEATTLE, Feb. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data on the utility of SeptiCyte™...
Immunexpress.com

Immunexpress Announces Presentations at the 45th Annual Society of Critical Care Medicine Congress on the Utility of SeptiCyte™ LAB

SEATTLE, Feb. 10, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data on the utility of SeptiCyte® Lab in both adult and pediatric populations to aid in the clinical assessment of sepsis in critical care patients will be presented...
Immunexpress.com

Immunexpress Releases Key Performance Data on SeptiCyte™ LAB in PLOS Medicine Publication

SEATTLE, Dec. 8, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis in PLOS Medicine. SeptiCyte® Lab is a rapid molecular assay that measures a patient's gene expression...
Immunexpress.com

Immunexpress Appoints Dr. Roy Davis Chief Medical Officer

SEATTLE, Oct. 22, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the  appointment of Roy F. J. Davis, Ph.D., M.D., M.H.A., as Chief Medical Officer. “Dr. Davis has over 30 years of experience providing and directing patient care for multiple...
Immunexpress.com

Immunexpress Appoints Dr. Bea Arnold to Board of Directors

SEATTLE, Sept. 29, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that Dr. Bea Arnold has joined the Company's Board of Directors. “We are delighted to welcome Dr. Arnold to our Board of the Directors,” said Roslyn Brandon, President and...
Immunexpress.com

Immunexpress to Present Data on SeptiCyte™ at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever”

SEATTLE, Sept. 16, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today that Dr. Therese Seldon, Vice President of Operations, will present data on SeptiCyte® technology at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of...
Immunexpress.com

Immunexpress Supports World Sepsis Day 2015

Call for Action on Sept. 13 Includes Awareness, Education and Funding Initiatives to Help Reverse Global Increase in Numbers of Deaths from Sepsis    Video Interviews on the Immunexpress Website Highlight the Need for Faster Diagnosis of Sepsis  SEATTLE, Sept. 10, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed...